About replimune group inc - REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
REPL At a Glance
Replimune Group, Inc.
500 Unicorn Park Drive
Woburn, Massachusetts 01801
| Phone | 1-781-222-9600 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -247,297,000.00 | |
| Sector | Health Technology | Employees | 479 | |
| Fiscal Year-end | 03 / 2026 | |||
| View SEC Filings |
REPL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.807 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.454 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.202 |
REPL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -516,277.662 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
REPL Liquidity
| Current Ratio | 7.952 |
| Quick Ratio | 7.952 |
| Cash Ratio | 7.758 |
REPL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -47.601 |
| Return on Equity | -62.579 |
| Return on Total Capital | -50.263 |
| Return on Invested Capital | -52.925 |
REPL Capital Structure
| Total Debt to Total Equity | 18.316 |
| Total Debt to Total Capital | 15.48 |
| Total Debt to Total Assets | 13.815 |
| Long-Term Debt to Equity | 17.358 |
| Long-Term Debt to Total Capital | 14.671 |